

ForPatients

by Roche

Influenza

A study to look at the safety and effectiveness of baloxavir marboxil in treating children with influenza aged between 1 and <12 years (miniSTONE-2)

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

Trial Status
Completed

Trial Runs In
7 Countries

Trial Identifier
NCT03629184 2018-002169-21
CP40563

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to <12 years of age) with influenza-like symptoms.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03629184 2018-002169-21 CP40563
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=1 Year & <= 11 Years

Healthy Volunteers
No
